<?xml version="1.0" encoding="UTF-8"?>
<p>APOA4, a 46â€‰kDa plasma apolipoprotein, is synthesized predominantly in the small intestine and is an antiatherogenic and antioxidative plasma glycoprotein involved in reverse cholesterol transport. The increased expression of APOA4 was found in chronic kidney disease (CKD) patients [
 <xref rid="B21" ref-type="bibr">21</xref>]. In previous studies, plasma APOA4 levels were increased in DM patients, especially in noninsulin-dependent diabetes mellitus (NIDDM) patients [
 <xref rid="B22" ref-type="bibr">22</xref>, 
 <xref rid="B23" ref-type="bibr">23</xref>]. The increase in expression of APOA4 may be related to hypertriglyceridemia (hTG), hyperglycemia, hormonal dysregulation, inflammation, and to a lesser extent to HDL cholesterol level [
 <xref rid="B24" ref-type="bibr">24</xref>]. However, the metabolism pathway and relationship between APOA4 and DM were unclear.
</p>
